Search Results
58 Results Found for “neuroinflammation”
How advances in molecular understanding are shaping Parkinson's disease classification, patient stratification, and the future of personalized care Parkinson’s disease has historically been diagnosed and classified primarily according to clinical features. However, advances in genetics, molecular biomarkers, and our ...
Leading Alzheimer's disease experts share the therapeutic and research developments they believe had the greatest potential to transform diagnosis, treatment and prevention at the Alzheimer's Association International Conference (AAIC) 2026. The Alzheimer's Association International Conference (AAIC) 2026 showcased advances across the Alzheimer's ...
Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer's disease therapies and advancing our understanding of neuroinflammation. https://touchmedicalmedia-1.wistia.
Why this topic matters Autoimmune psychosis (AP) is conceptualized as a psychosis-dominant form of autoimmune encephalitis (AE). In contrast to ‘typical’ AE, in which seizures, impaired consciousness and focal deficits rapidly declare a neurological syndrome, patients with AP can initially ...
New Phase 2b data highlight the potential of targeting synaptic dysfunction to slow disease progression in dementia with Lewy bodies Dementia with Lewy bodies (DLB) remains an area of high unmet need, with no approved disease-modifying therapies and significant clinical ...
The Alzheimer’s and Parkinson’s Diseases Conference (AD/PD) 2026, held in Copenhagen, Denmark, brought together over 5,800 delegates to discuss advances across neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and related disorders. ...
Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 ...
The 19th European Headache Congress (EHC25) was held in Lisbon and brought together headache specialists, researchers and healthcare professionals from across Europe and beyond. Under the theme Transforming challenges into solutions, the congress focused on translating advances in headache science into meaningful improvements in clinical care. The meeting addressed key challenges in the prevention, diagnosis and treatment of headache and facial pain disorders, with an emphasis on bridging basic science, translational research and real-world clinical practice.
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
The 11th Congress of the European Academy of Neurology (EAN) delivered ground-breaking insights across neurology, showcasing how precision medicine is reshaping clinical practice. Taken from the EAN Highlights and Breaking news session presented 24 June 2025 (PLEN03), touchNEUROLOGY summarizes the key highlights across dementia, headache, movement disorders, cerebrovascular and neuromuscular diseases.
Nominated as a touchNEUROLOGY Future Leader 2025, and in collaboration with the National MS Society, we speak with Dr Riley Bove (Associate Professor, UCSF Weill Institute for Neurosciences, CA, San Francisco, USA), a clinician-researcher dedicated to advancing understanding of brain health through the lens of neuroimmunology, with a unique focus on women's health in MS.
In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.
In this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
The FDA has approved tenecteplase (TNKase) for the treatment of acute ischemic stroke (AIS) in adults, marking the first new stroke-specific thrombolytic approval in nearly three decades. Administered as a single five-second intravenous bolus, tenecteplase allows for faster administration compared to the current standard of care alteplase, which is administered as a bolus-plus-infusion regimen.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
